Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals

Drug Profile

Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals

Alternative Names: BMS-936558; MDX-1106; Nivolumab BMS; ono-0123; ONO-4538; Opdivo

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medarex; Ono Pharmaceutical; Sidney Kimmel Cancer Center
  • Developer Aduro BioTech; AIO Studien gGmbH; Australian and New Zealand Urogenital and Prostate Cancer Group; Bavarian Nordic; Big Ten Cancer Research Consortium; Bristol-Myers Squibb; Clovis Oncology; Dana-Farber Cancer Institute; Duke University Medical Center; Eisai Inc; Eli Lilly; Emory University; European Thoracic Oncology Platform; Exelixis; Frontier Science foundation; Grupo Espanol Multidisciplinar de Melanoma; Hoosier Cancer Research Network; Incyte Corporation; Intergroupe Francophone de Cancerologie Thoracique; Janssen Biotech; Janssen Research & Development; M. D. Anderson Cancer Center; Massachusetts General Hospital; Medarex; Nantes University Hospital; National Cancer Center (Tokyo); National Cancer Centre (Singapore); National Cancer Institute (USA); Nektar Therapeutics; Neon Therapeutics; Netherlands Cancer Institute; Northwestern University; Ono Pharmaceutical; Pharmacyclics; Seattle Genetics; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; The University of Montreal Hospital Research Center; University College London; University of Texas M. D. Anderson Cancer Center; Zucero Therapeutics
  • Class Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma; Malignant melanoma; Hepatocellular carcinoma; Hodgkin's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
  • Registered Colorectal cancer; Hepatocellular carcinoma
  • Preregistration Mesothelioma
  • Phase III Glioblastoma; Multiple myeloma; Oesophageal cancer; Ovarian cancer; Small cell lung cancer
  • Phase II/III Non-Hodgkin's lymphoma
  • Phase II Acute myeloid leukaemia; Adrenocortical carcinoma; Brain metastases; Breast cancer; Cancer; Carcinomatous meningitis; Cervical cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Genitourinary disorders; Myelodysplastic syndromes; Pancreatic cancer; Penile cancer; Prostate cancer; Soft tissue sarcoma; Testicular cancer; Thyroid cancer; Uterine cancer; Uveal melanoma
  • Phase I/II Bladder cancer; Haematological malignancies; Peritoneal cancer; Rectal cancer; Sepsis; Solid tumours
  • Phase I Biliary cancer; Chronic myeloid leukaemia; Glioma; Hepatitis C

Most Recent Events

  • 16 Mar 2018 Registered for Hepatocellular carcinoma (Late-stage disease, Second-line therapy or greater) in Taiwan (IV)
  • 15 Mar 2018 Bristol-Myers Squibb initiates a phase I/II trial in Diffuse large B cell lymphoma (Second-line therapy or greater, Combination therapy) in USA (IV) (NCT03305445)
  • 15 Mar 2018 Bristol-Myers Squibb plans a phase I/II trial for Cancer (Late-stage disease, Combination therapy, Metastatic disease, Inoperable/Unresectable) in April 2018 (NCT03459222)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top